On January 7, the U.S. Food and Drug Administration (FDA) amended the emergency use authorization (EUA) for the Moderna COVID-19 vaccine to shorten the time between the completion of a primary series of the vaccine and a booster dose to at least 5 months for individuals aged 18 years and older.
“The country is in the middle of a wave of the highly contagious omicron variant, which spreads more rapidly than the original SARS–CoV-2 virus and other variants that have emerged,” said Peter Marks, MD, PhD, Director of the FDA’s Center for Biologics Evaluation and Research. “Vaccination is our best defense against COVID-19, including the circulating variants, and shortening the length of time between completion of a primary series and a booster dose may help reduce waning immunity. [This] action also brings consistency in the timing for administration of a booster dose among the available mRNA vaccines. We encourage everyone to get vaccinated—it’s never too late to get your COVID-19 vaccine or booster.”
The most commonly reported side effects by individuals who received a booster dose of the Moderna COVID-19 vaccine after completion of a two-dose primary series were pain, redness, and swelling at the injection site, as well as fatigue, headache, muscle or joint pain, and chills. The fact sheets for recipients and caregivers and for health-care providers include information about the potential side effects, as well as the risks of myocarditis and pericarditis.
The amendment to the EUA was granted to ModernaTx Inc.
